drugset / Trial / NCT04391621

Efficacy of Adipose Derived Stromal Vascular Fraction in the Treatment of Keloids

NCT04391621

Phase 2 Unknown 30 enrolled Makerere University
RandomizedParallel-groupTriple-blindTreatment

Summary

Keloids affect upto 16% of Africans causing significant cosmetic, functional and psychosocial distress. Available treatment options are associated with high recurrence and highly variable symptom relief. Autologous adipose derived stem-cells(ADSCs) have been described to have a potential therapeutic benefit in treating keloids. Investigators will compare intra-lesion single dose Autologous Adipose Derived Stem Cells harvested from abdominal fat to Triamcinolone Acetanoide among 15 patients with keloids treated at Mulago National Referral Hospital in Kampala Uganda between September 2020 and August 2021. These patients will be followed up for keloid volume change at three months following treatment.

Timeline

Start
2021-05-01
Primary completion
2021-12-30
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Triamcinolone Acetonide Other / unclassified 40 mg/ml Other

Indications